Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Common Equity (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Common Equity for 7 consecutive years, with -$2.1 billion as the latest value for Q4 2025.

  • Quarterly Common Equity fell 42.41% to -$2.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.1 billion through Dec 2025, down 42.41% year-over-year, with the annual reading at -$2.1 billion for FY2025, 42.41% down from the prior year.
  • Common Equity hit -$2.1 billion in Q4 2025 for BridgeBio Pharma, down from -$1.9 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of -$389.4 million in Q1 2021 to a low of -$2.1 billion in Q4 2025.
  • Historically, Common Equity has averaged -$1.2 billion across 5 years, with a median of -$1.2 billion in 2023.
  • Biggest five-year swings in Common Equity: crashed 915.96% in 2021 and later rose 19.86% in 2024.
  • Year by year, Common Equity stood at -$867.0 million in 2021, then tumbled by 43.41% to -$1.2 billion in 2022, then dropped by 8.02% to -$1.3 billion in 2023, then decreased by 8.54% to -$1.5 billion in 2024, then plummeted by 42.41% to -$2.1 billion in 2025.
  • Business Quant data shows Common Equity for BBIO at -$2.1 billion in Q4 2025, -$1.9 billion in Q3 2025, and -$1.8 billion in Q2 2025.